Studies have shown that targeting ferroptosis and cuproptosis by inhibiting the xCT-GSH-GPX4 pathway can synergistically enhance the effect of DSF/Cu in MDS treatment, providing insights for this combined therapeutic strategies (Li H. et al., 2024). The gene discussed is SLC7A11; the disease is myelodysplastic syndrome.